Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory maintenance dosing study […]